Thermo Fisher Scientific Inc. has extended its state-of-the-art manufacturing capability in Shanghai, China, for the production of Thermo Scientific Nunc Cell Factory single-use, certified-sterile bioprocessing systems. This announcement forms part of a continuing strategy of global investment in the regional production of its high-quality bioprocessing products, to support the local bioproduction of vaccines, cell and protein therapeutics. The increased capacity builds on Thermo Fisher Scientific’s position as the leading developer of single-use products for bioproduction, while meeting the demands of the European, North American and Asia-Pacific bioproduction markets.
The Shanghai facility complements the Nunc Cell Factory production sites in Rochester, New York, and Roskilde, Denmark. Commenting on the new investment, Chuck Kummeth, president of the laboratory consumables division of Thermo Fisher Scientific said, “The Rochester, Roskilde and Shanghai sites are designed to meet local and international demands both now and in the future, and will facilitate the effective streamlining and continuity of supply for our growing customer base. Our aim is to provide regional biopharma production sites with the fastest and most efficient delivery of cell culture consumables, and to enable us to do this, we are currently investing heavily in the APAC region in particular.”
Stringent quality control procedures are in place across all of the global sites to guarantee the consistent delivery of highest-quality products. Referring to Thermo Fisher Scientific’s drive for market-leading quality, Kummeth said, “Product quality is paramount, and the provision of cell culture platforms and containment systems that are specifically developed to facilitate easy scale-up and commercialization of bioproduction processes, have been key to our success so far.”
Thermo Scientifics’ bioprocessing products portfolio is complemented by media supplements, process liquids and cell culture sera, and the extended production facilities in Shanghai follows a recently opened site in Beijing dedicated to the hydration of cell culture media, and a joint venture in Lanzhou, China, for the collection, processing and selling of serum into local markets. Further multi-million dollar investments have been made at production sites based in Cramlington, UK and Logan, Utah.
Filed Under: Drug Discovery
